Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026.
An archived copy of the webcast will be available on the events section of the Company’s website for approximately 90 days following the live presentation.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce’s lead product candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of MPS IIIB, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261015117605/en/
Media
Heidi Chokeir
Inizio Evoke Comms
[email protected]
[email protected]
Investors
Monique Kosse
Gilmartin Group
[email protected]
[email protected]
KEYWORDS: California United States North America
INDUSTRY KEYWORDS: Health Neurology Clinical Trials Research Science Pharmaceutical Biotechnology
MEDIA:
| Logo |
 |